Mr. Woods has over three decades of experience in the biopharmaceutical sector, and has served as chief operating officer (COO) of Scholar Rock, Inc. since April 2025. Previously, Mr. Woods served as COO of argenx where he led the company through its transition from an R&D organization to a global commercial organization. During this time, he oversaw key teams in preparation for argenx’s first product launch, including sales, marketing, market access and reimbursement, business operations, patient services and medical affairs. Prior to argenx, Keith served as senior vice president of North American operations for Alexion Pharmaceuticals, Inc. (Alexion), where he managed a team of several hundred people in the U.S. and Canada and was responsible for more than $1 billion in annual sales. Prior to joining Alexion, Mr. Woods held various positions of increasing responsibility within Roche, Amgen, and Eisai Co., Ltd., over a span of 20 years. Keith currently serves on the Board of Directors of Neurogene Inc. and TScan Therapeutics. He holds a Bachelor of Science in marketing from Florida State University.